Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
LXEO
LXEO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LXEO News
Lexeo Therapeutics Announces Investor Conference Schedule
Feb 05 2026
Newsfilter
Lexeo Therapeutics Announces Key Senior Leadership Appointments
Jan 27 2026
Newsfilter
Telsey Raises Five Below Inc Price Target to $240
Jan 13 2026
Benzinga
U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%
Jan 12 2026
Benzinga
IBM and LXEO Options Show Significant Volume Surge
Jan 09 2026
NASDAQ.COM
Lexeo Therapeutics Partners with J&J to Advance Gene Therapy for Cardiovascular Diseases
Jan 08 2026
NASDAQ.COM
Valvoline Analyst Starts Coverage Optimistically; Check Out Thursday's Top 5 Initiations
Dec 18 2025
Benzinga
Biotech Sector Sustains After-Hours Trading Gains
Dec 18 2025
NASDAQ.COM
Lexeo Therapeutics to Host Virtual Event on Managing PKP2-Associated Arrhythmogenic Cardiomyopathy
Dec 04 2025
Globenewswire
Chardan Capital Reaffirms Buy Rating on Lexeo Therapeutics with $17 Price Target Intact
Nov 06 2025
Benzinga
Innovative Approaches to Address Challenging Medical Conditions Beyond Conventional Medications
Oct 21 2025
Newsfilter
Lexeo Therapeutics Reveals Pricing for Public Offering and Simultaneous Private Placement
Oct 17 2025
Newsfilter
Lexeo Therapeutics Unveils Plans for Common Stock and Pre-Funded Warrants Offering
Oct 16 2025
Newsfilter
Top Analysts Recommend 3 Best Stocks to Purchase Now, 10/15/2025
Oct 15 2025
TipRanks
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Oct 08 2025
PRnewswire
Lexeo Therapeutics Reports Advancements in FDA Talks for Fast-Track Approval and Encouraging Interim Clinical Results for LX2006 in Friedreich Ataxia Cardiomyopathy
Oct 07 2025
Newsfilter
Show More News
